GlassScriptPhysician profile
Robby Ranbir Singh
NPI 1801239454
$10,468.57
in general payments reported to CMS, 2019-2025
37 companies · $2,159 in 2025
The $2,159 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,498 · 2020: $1,212 · 2021: $675 · 2022: $629 · 2023: $2,626 · 2024: $1,670 · 2025: $2,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,906 · Travel and Lodging: $1,549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,906.34 |
| Travel and Lodging | $1,548.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,800.42 | 2019-2025 | Jot Dx, Coroflow, Diamondback Peripheral |
| Bard Peripheral Vascular, INC. | $1,174.92 | 2021-2023 | Venclose Maven Catheter |
| Boston Scientific Corporation | $952.43 | 2023-2025 | Varithena Administration Pack, Lux-Dx Insertable Cardiac Monitor, Cds - Mct/Cem Monitoring |
| Boehringer Ingelheim Pharmaceuticals, INC. | $695.34 | 2019-2025 | Jardiance |
| Philips North America LLC | $610.58 | 2020-2025 | (Ck7) Extended Holter, (Ck4) Mcot, Laser Cvx300 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $481.42 | 2020-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $480.08 | 2021-2025 | |
| Pfizer INC. | $446.16 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $428.71 | 2020-2025 | Farxiga, Lokelma |
| Merck Sharp & Dohme LLC | $427.34 | 2021-2025 | Verquvo |
| Edwards Lifesciences Corporation | $348.27 | 2019-2025 | Sapien 3 Ultra Resilia |
| Medtronic, INC. | $290.38 | 2025 | Aurora Ev-Icd Mri Surescan, Symplicity G3, Venaseal |
| Amgen INC. | $263.73 | 2019-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $231.45 | 2019 | |
| Medtronic Vascular, INC. | $226.49 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $207.34 | 2023-2024 | Auryon Laser System 100-120 Vac, Venacure 1470 Pro |
| Janssen Pharmaceuticals, INC | $186.41 | 2021-2024 | Xarelto |
| Kestra Medical Technology Services, INC. | $176.77 | 2022-2025 | Assure Wcd |
| Scpharmaceuticals INC. | $148.86 | 2024-2025 | |
| W. L. Gore & Associates, INC. | $138.63 | 2022-2025 | Gore Cardioform Septal Occluder |
| Novo Nordisk INC | $121.28 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Cardiovascular Systems INC. | $62.95 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $60.32 | 2019-2022 | |
| Penumbra, INC. | $60.00 | 2025 | Indigo System |
| Bayer Healthcare Pharmaceuticals INC. | $59.10 | 2022-2023 | |
| Alnylam Pharmaceuticals INC. | $55.24 | 2023-2024 | Onpattro |
| Esperion Therapeutics, INC. | $51.86 | 2020-2021 | |
| Irhythm Technologies, INC. | $43.67 | 2023 | Zio Xt Patch |
| Astellas Pharma US INC | $43.02 | 2020-2021 | |
| Amarin Pharma, INC. | $42.29 | 2020-2021 | |
| Cardiva Medical, INC. | $39.55 | 2024 | Savvywire, Cardiva Vascade Mvp Vvcs 6-12f |
| Inari Medical, INC. | $26.13 | 2020 | |
| Atricure, INC. | $25.00 | 2024 | |
| Abiomed | $17.46 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $16.36 | 2024 | |
| Impulse Dynamics (USA) INC. | $16.36 | 2023 | Optimizer |
| Cvrx, INC. | $12.25 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robby Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.